shanghai
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
https://www.searates.com/shipping/list/?id=439671
What does that mean? Is it clear?
Afrezzauser?
@afrezzauser
I love my #afrezza I pick up 3 months at a time now with 1 prescription. #t1d #diabetes Media only focuses on "inhaled" .Focus on onset&exit
--------------------------------------------------------------------------------
Simple calculation: the original one month need 3 boxes (one month a rx), now 3 months need 9 boxes (3 months a rx)
------------------------------------------------------------------------------
My math is very poor, if refill are like this, is not the number of refill smaller?
----------------------------------------------------------------------------
Sanofi is a commercial company for decades
Mnkd is a research and development company, now just started commercial,
You can not call a one-year-old baby, start talking, running
nrx;102-109-105-104-125-124-133-134-123-142-117-155
Great achievement
my God
Sanofi has script every week?
Afrezzauser?
@afrezzauser
I love my #afrezza I pick up 3 months at a time now with 1 prescription. #t1d #diabetes Media only focuses on "inhaled" .Focus on onset&exit
--------------------------------------------------------------------------------
Simple calculation: the original one month need 3 boxes (one month a rx), now 3 months need 9 boxes (3 months a rx)
---------------------------------------------------------------------------
3Q 2016 $ 570,000
4Q 2016 $ 1.2 million
Cliff Notes/Paraphrase from Nate's Inter-Issue Commentary
Although SP has continued to slide, in Nate’s opinion, there has been nothing to justify this price slide … but it may keep sliding. Nate considered the April 7th 8-K as a non-event. He said there already was a “Change of Control” with several of its top managers. This renewal includes the newly hired executives, since MNKD is transitioning from a manufacturing company to an actual pharmaceutical company. Also, considering the low SP, it may help with the possibility of a hostile takeover. In all, Nate suggests not reading too much into that 8-K. And as of now, there is no buyout offer on the table.
Nate reviewed the Deerfield debt obligations. Although the first $10m payments have been arranged, Nate suggested that the second round has put investors into panic-mode. Nate does not know what Matt’s plans are for that second round of debt payment. Nate spoke with Matt on the phone last Saturday, but Matt was not able to discuss much about that, but Nate offered some observations to put our minds at rest a little.
First, MNKD still owes Deerfield tens of millions of dollars, so Deerfield will want MNKD to succeed. Not only will a healthy, vibrant MNKD insure that Deerfield will get repaid their debt, there will also be significant upside of additional payments they will be entitled to if/when MNKD hits certain milestones for Afrezza sales. So, Deerfield will probably continue to work with, rather than against MNKD for as long as possible.
Second, since Matt is moving forward with the rollout and promotion of Afrezza on many fronts (and hiring many to accomplish that), so he seems to have his focus on the game plan of making Afrezza a success, rather than planning bankruptcy.
Finally, as time moves on, we get closer to hitting the “inflection point” where enough doctors finally feel comfortable enough with the results they have seen in a handful of their patients that they will start to more aggressively move the rest of their practice over to Afrezza.
Nate has been getting first-hand feedback from Afrezza patients that he knows along with the social-media feedback. He believes more strongly than ever that Afrezza really is all that we hoped it would be, and if the company can survive the near-term, the current market cap is WAY too low, which suggests that the stock should be bought hand over fist at these levels.
However, he understands that most of his readers (and us) are too deep into this investment, so, until we get some more clarity into the near-term financial outlook, he cautions to take a wait and see approach since “trends often go on for far longer than seems reasonable”. He said we are approaching the “extreme fear” end of the fear/greed spectrum or the pendulum swing. Although $.92 is a crazy SP, it could get cut in half again before cooler heads prevail.
So, hang in there. ?
1, how much time do you play the stock?
2, do you know mnkd real world?
3, you know that extremes meet?
4, the stock price changes must be the company's real situation?
Sanofi spent 200 million dollars before 2016, messing up mnkd sales
Sanofi is now spending $ 200 million to short the price of mnkd stock
3Q 2016 $ 570,000
4Q 2016 $ 1.2 million
MannKind Sponsors New Diabetes Reality TV Show, 'Reversed'
www.healthline.com/diabetesmine/mannkind-sponsors-reversed-reality-tv-show-diabetes
Written by Mike Hoskins
Published on May 2, 2017
Strong Afrezza endorsement by Amy Tenderich and Mike Hoskins.
Excerpts follow.
Really, Diabetes Reality TV?
Yup, Mattocks describes it as a docu-series reality show that is "part of his journey." Take a look at this video promo just released in late April.
To be clear, this is not the first time a reality TV show has dabbled in life with diabetes -- from the MTV TruLife episode back in 2012 that featured three T1 PWDs, to a T1 teen mom, and the American Idol competition in 2015 featuring Adam Lasher, a T1 nephew of Carlos Santana. Apparently, even rap legend Dr. Dre (who lives with T2D himself) has been talking about creating his own D-related reality show, given his complication-ridden T2 that's led to him losing his vision.
But Reversed does appear to be the first national reality show 100% dedicated to diabetes and its management.
What you'll be watching is five PWDs in a house surrounded by beaches and palm trees at the Milbrooks Resort island retreat in exotic Montego Bay, Jamaica.
In a recent podcast, Mattocks talked with three of the PWDs who participated in thes show -- two type 2s, and a T1 who just started on Afrezza after being on the show. Interestingly, during the 15-minute podcast, the trio talked about how they didn't expect the show to be as life-changing as it was, helping them acheive better D-management and health habits. One of the T2s named Jerome said it's "exactly what he needed" to change his mindset and since the show's production wrapped up, he has not only lost weight and felt better, but with help from his doctor he's managed to dramatically cut down his insulin intake and other medications.
They all agreed the show wasn't keyed in on or overbearing on messages of weight loss, low-carb or plant-based eating, but rather about finding what works best for each of them in making healthier choices. The T1, a woman named Felice, spoke on the podcast about her 43 years with T1D and how she was "heading into the deep hole of D-burnout" before going on Reversed, and since then she's been able to change her attitude and perspective. She started Afrezza in mid-April, which she says has translated to only one basal injection per day instead of seven multiple daily injections, fewer hypos and much more stable BGs.
These personal PWD accounts were certainly very convincing that the show has merit.
Beyond this introductory season, Charles is pondering future options -- a live-recorded version, celebrity cast, and even going beyond diabetes into other health conditions.
"We think we have something special here, and we do think we're going to be changing lives," he said
Sponsored by Afrezza / MannKind Corp.
As noted, MannKind is currently the show's sole sponsor, so they get fully play, including a display ad on the show's website with an image of the late Alfred Mann, who created the company and passed away in early 2016.
MannKind's Chief Operational Officer Mike Castagna tells us that as sponsors, they have no involvement in the show's development or content. While one participant will be using and demonstrating Afrezza on the air, that wasn't a requirement and was not even intentional product placement.
Castagna says they've created a storyboard for a commercial -- something that show coordinators say will be 1-minute long, rather than 30 seconds as the FDA usually mandates for pharma ads. (We mentioned this in our recent coverage of MannKind's wish to become "the Uber of diabetes.")
Whether this helps MannKind's business with Afrezza is anyone's guess. But you can't fault the company for thinking outside the box here.
Castagna recognizes that the word "reversed" is controversial, particularly when you have celebrities such as Halle Berry and Drew Carrie who've used that word to essentially claim erasing their disease. He says it's clear that diabetes can't be erased, and it's about educating the PWD masses on management basics.
"How many shows focus on diabetes? I can't think of any," Castagna says. "We have shows focusing on plastic surgery, emergency rooms, on pain, but there's nothing out there like this to raise awareness. That's why it's important that somebody does something, and why MannKind is sponsoring this. We can debate the word 'reversed,' but I don't think that's the right debate to be having -- even though I wouldn't argue it shouldn't be used. But the debate should be why we aren't we raising awareness about achieving better health outcomes? That's what I hope comes out of the show."
Meanwhile, our team is rooting for Afrezza to do well on the market; Amy and I both currently use it, so we're making no bones about the fact that we think it's a good drug that can help many PWDs.
If all goes well, this show could be a win-win for everyone. We shall see...
It deserves a chance, if nothing else. So keep an eye on your TV listings this summer, D-Friends.
frangipan:
This may have already been posted, but I thought I would share in the event it hadn't.
I was in an neurologist's office (big practice kind of place), and in the exam room there was a monitor of sorts. "Ads" would cycle through there, about eating well, blah, blah, and I wasn't paying attention to it. When the nurse came in to talk to me, I was looking at her and behind her was the screen and I saw Afrezza come up. So, at least they are doing this.
I asked a question today
If mnkd went bankrupt, afrezza failed; then the biggest winners were not Sanofi?
If mnkd succeeds, afrezza victory; then the biggest failure side is not Sanofi?
Because English is not good, usually I do not participate in the comments, afraid of the wrong words, I try to send short content.
my God
Sanofi has script every week?
Brendan Hyland
@brendanphyland
3 MONTHS LATER
Brendan28h
I absolutely love Afrezza. It has been a game changer for me. 1st September 2015 was my first inhale. I have read here people talking about energy like nothing else having ate a carbohydrate meal, no spikes, the idea of first phase insulin stabilizing BG levels. I could not believe the change that happened in my body. I had a number of health issues before Afrezza which disappeared within 24 hours of my first inhalation.m It's not a miracle cure and requires effort but the upshot is amazing and worth the initial time input. Basal insulin may need to be increased. MIne is Tresiba. I am awaiting to get more Afrezza as I am currently in the UK and it is not available here. Presently I use Porcine Neutral but the onset is one hour and the tail is 10 hours and so I have had some sneaky lows that have incapacitated me. Here are the benefits of Afrezza. It needs more noise to be created about it and diabetics to demand that they can try it.
Advantages
1. My energy levels soared on Afrezza. I have never felt this good in all my life. I am not tired all the time. I have more energy and I am definitely more productive.
2. I am not having to micro-manage diabetes.
3. I am prescribed Lyrinel for excessive sweating as I have suffered from this for well almost 20 years and it’s detrimentally affected me over the last 10. I have had botox to provide temporary relief and I have needed to use aluminium chloride salts to control it(Odaban). My sweating has stopped completely on Afrezza. I have stopped taking Lyrinel completely.
4. I have much more feeling in the tips of my fingers and my toes. I have never had an issue with this but my sense of touch in my extremities has improved. I am not saying it was bad to start off with. In fact I have never mentioned this and my pulses and circulation have always been good but there is a huge difference in sensation for me.
5. I do not get pains in my calves and shins. This was very noticeable and I have found that co-codamol helps. I have stopped requesting co-codamol in my repeat prescription as the pain is no more.
6. My docs are amazed at the improvement in my retinopathy due to reduced glycaemic variability and a more stable profile.
Sanofi spent 200 million dollars before 2016, messing up mnkd sales
Sanofi is now spending $ 200 million to short the price of mnkd stock
Cliff Notes/Paraphrase from Nate's Inter-Issue Commentary
Although SP has continued to slide, in Nate’s opinion, there has been nothing to justify this price slide … but it may keep sliding. Nate considered the April 7th 8-K as a non-event. He said there already was a “Change of Control” with several of its top managers. This renewal includes the newly hired executives, since MNKD is transitioning from a manufacturing company to an actual pharmaceutical company. Also, considering the low SP, it may help with the possibility of a hostile takeover. In all, Nate suggests not reading too much into that 8-K. And as of now, there is no buyout offer on the table.
Nate reviewed the Deerfield debt obligations. Although the first $10m payments have been arranged, Nate suggested that the second round has put investors into panic-mode. Nate does not know what Matt’s plans are for that second round of debt payment. Nate spoke with Matt on the phone last Saturday, but Matt was not able to discuss much about that, but Nate offered some observations to put our minds at rest a little.
First, MNKD still owes Deerfield tens of millions of dollars, so Deerfield will want MNKD to succeed. Not only will a healthy, vibrant MNKD insure that Deerfield will get repaid their debt, there will also be significant upside of additional payments they will be entitled to if/when MNKD hits certain milestones for Afrezza sales. So, Deerfield will probably continue to work with, rather than against MNKD for as long as possible.
Second, since Matt is moving forward with the rollout and promotion of Afrezza on many fronts (and hiring many to accomplish that), so he seems to have his focus on the game plan of making Afrezza a success, rather than planning bankruptcy.
Finally, as time moves on, we get closer to hitting the “inflection point” where enough doctors finally feel comfortable enough with the results they have seen in a handful of their patients that they will start to more aggressively move the rest of their practice over to Afrezza.
Nate has been getting first-hand feedback from Afrezza patients that he knows along with the social-media feedback. He believes more strongly than ever that Afrezza really is all that we hoped it would be, and if the company can survive the near-term, the current market cap is WAY too low, which suggests that the stock should be bought hand over fist at these levels.
However, he understands that most of his readers (and us) are too deep into this investment, so, until we get some more clarity into the near-term financial outlook, he cautions to take a wait and see approach since “trends often go on for far longer than seems reasonable”. He said we are approaching the “extreme fear” end of the fear/greed spectrum or the pendulum swing. Although $.92 is a crazy SP, it could get cut in half again before cooler heads prevail.
So, hang in there. ?
The incidence of adult needle phobia, ranked at 10% in a 1995 study, has been steadily growing. A study by Dr. Taddio in 2012 found a prevalence of 24% of adults. Similarly, a a 2012 survey by Target found 23% of those who didn’t get a flu shot avoided it because of the needle. For children, the incidence changed from 25% (Hamilton) to 63% (Taddio) — 252% increase in less than 2 decades. Our NIH research showed children with high needle fear were 2.5x less likely to start their HPV series than those with low fear. Fear of needles is a barrier to health.
As fear of needles has risen, public health implications are already being seen. The Taddio Study found noncompliance with vaccination due to fear in 7% of adults and 8% of children. According to a study of patients who DID go for travel vaccinations, 22% of adults fear needles enough to take risks with their health; the irony is that this study was DONE at a travel immunization clinic. What about patients who didn’t even go to the clinic to be available to ask? Studies from Japan to Thailand show that up to 75% of people do not donate blood due to fear, which affects our emergency safety system. Depending on the types and severity of the needle phobia, health risks may vary.
51% of adults with Type 2 Diabetes delay starting insulin due to fear; 94% feel fear reactions every time they inject. (Aronson R, DIABETES TECH & THERAP 2012 14(8):741-7; Kruger DF Diabetes met 2015:8;49-56).
---
Insulin pens are less painful than normal syringes but because pens are much more expensive than syringes, pens may be less prevalent for global treatment of diabetes than in the USA and wealthier European countries. Alternatives like inhaled insulin such as Afrezza may be more widely accepted by physicians in other countries where insulin is commonly injected by syringes rather than pens.
internationalpharmacy.com/products/afrezza-inhalation-cartridges-insulin-regular
Strength Size Manufacturer NDC Price
4/8 i.u. 30+60 Mannkind 47918-0882-36 $444.93
4/8 i.u. 60+30 Mannkind 47918-0884-63 $403.11
4 i.u. 90 Mannkind 47918-0874-90 $361.13
4/8 i.u. 90+90 Mannkind 47918-0880-18 $862.66
12/8 i.u. 30+60 Mannkind 47918-0894-63 $506.04
Each kit contains 90 cartridges and 2 inhalers. It is recommended that this item be shipped refrigerated.
InternationalPharmacy.com is not an authorized seller of any pharmaceutical manufacturer. Internationalpharmacy.com purchases pharmaceutical products from third parties for resale and is in no way affiliated with, authorized or sponsored by, or related to, any pharmaceutical manufacturer.
Restrictions
internationalpharmacy.com/restrictions
Australia
Schedule 4 and schedule 1 drugs require prescription for personal import. Limit each order to 3 months supply and 14 months supply per year.
Prescription should be from an Australian physician. It is recommended that a copy of the prescription accompany the shipment. Customs office may require you to present your prescription before they clear your package.
Belgium
Prescription drugs should be no more than 3 months’ supply.
Non-prescription drugs should be limited to 5 pieces of each item.
Prohibited items: Melatonin, Viagra
shipments to private individuals intended for personal use do not require import license provided value does not exceed 15,000 belgian francs (approximately US$430.00)
China
Import of prescription drugs is subject to approval of Health Ministry however import for personal use is exempt from official approval.
Prescription drugs should be no more than 3 months’ supply.
Non-prescription drugs should be limited to 5 pieces of each item.
If the declared value of medication is more than CNY 400 then duties must be paid by recipient.
Canada
Pharmacists, Practitioners, drug manufacturers and Foreigners while traveling thru Canada can import prescription drugs.
Canadian residents may not import prescription drugs for personal use unless they do so thru the emergency medical act. Information can be obtained from Canadian practitioner.
Products that are not listed Under Schedule F of the Food and Drug Act may be imported into Canada for personal use, even if they are listed as prescription drugs here in USA.
You may not order on line for shipment to Canada. Please contact us for any orders.
You can go to following link in order to check schedule for drugs in Canada:
search.hc-sc.gc.ca/cgi-bin/query?mss=dpd/english/active/simple
*Please note that we are unable to mail most items to Canada as explained under Country Restrictions.
India
Doctor’s prescription must accompany personal shipments.
Substantial Duty may apply (30% or more)
Israel
Import of medicine for personal use is OK provided recipient has prescription.
Copy of prescription should accompany shipment.
Prescription drugs should be no more than 3 months’ supply.
Non-prescription drugs should be limited to 5 pieces of each item.
Substantial Duty may apply.
Pharmacists, hospitals and Labs recognized by the state can import medicines in small amounts without obtaining a license.
Japan
Prescription or import permit is not required for import of non-controlled prescription drugs intended for personal use and not for commercial purposes. Prescription drugs should be limited to one month’s supply or one bottle per shipment. Non-prescription drugs should be no more than 5 pieces. Medicines mailed to Physicians, clinics, hospitals or any commercial address may require import permit.
United Arab Emirates
Import of medicines require prior authorization and approval of the health ministry.
Prescription must accompany all packages.
Prescription drugs should be no more than 3 months’ supply.
Non-prescription drugs should be limited to 5 pieces of each item.
Mexico
Medicines are admitted only by prior approval of the Department of Public Health in Mexico.
New Zealand
Prescription from a local physician must accompany all pacakges. Prescription drugs should be no more than 3 months’ supply. Non-prescription drugs should be limited to 5 pieces of each item.
Romania
Medicines intended for personal use do not require import permit, provided quantity is limited to one piece of each item.
Prescription drugs should be no more than 3 months’ supply.
Non-prescription drugs should be limited to 5 pieces of each item.
Saudi Arabia
Medicines are not admissible, unless accompanied by a medical prescription issued by a competent authority.
Prescription drugs should be no more than 3 months’ supply.
Non-prescription drugs should be limited to 5 pieces of each item.
Switzerland
Import of prescription drugs for personal use does not require an import permit or prescription however duties must be paid by recipient (approximately 20% of value).
Antibiotics require a prescription which must be attached to the commercial invoice.
Prescription drugs should be no more than 3 months’ supply.
Non-prescription drugs should be limited to 5 pieces of each item.
Pharmacists, hospitals and Labs recognized by the state can import medicines in small amounts without obtaining a license.
Taiwan
No license is required provided it is being imported for personal use and the value is less than US$1,000.00.
Nrx142 »refill39 made the first from 2016.06.30
-------------------------------------------------------------------------
(1)3Q 2016 $ 570,000
4Q 2016 $ 1.2 million
(2)nrx 102-109-105-104-125-133-134-123-142
Revealed a message in China, an American stock site, mnkd stock has a call Sanofi's investors are also often attack mnkd,
I think (trend now attack mnkd, that is, Sanofi attack mnkd)
I think (Sanofi past the attack mnkd sales, now Sanofi attack mnkd stock price)